Not Signed In - Genzyme Files For Approval Of Sevelamer Carbonate For Patients On Dialysis
Sat, 23 Dec 2006 08:00 AM EST
... Genzyme Corp. (Nasdaq: GENZ) announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration seeking approval of sevelamer carbonate for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Sevelamer carbonate will be marketed under the trade name Renvela(TM) (ren-VEL-uh). [click link for full article] ...
Related Topics
- Dialysis
- Peritoneal Dialysis
- Sevelamer
- Vaccine Testing & Approval
- Hemodialysis/dialysis
- Hemodialysis
- Seizures (in about half of patients)
- Kidney Failure and Dialysis
- Vaccinations For HIV/AIDs Patients
- What Your Female Patients Want to Know About Bladder Control
- Simethicone
- Smoking Cessation and Continued Risk in Cancer Patients
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
- Lithium Carbonate
- Calcium Carbonate
- Kidney Dialysis
- Peritonitis - dialysis associated
- Peritoneal Dialysis Dose and Adequacy
- Anemia in Kidney Disease and Dialysis
- Aluminum Hydroxide, Magnesium Carbonate Chewables
email this page
print this page
bookmark this page
feedback on this page
